

Beslut vid Fru Berta Kamprads styrelsemöte 27 april 2021

Mattias Aine, FBKS-2021-27

Advanced image-based characterization of the tumor microenvironment of triple-negative breast cancer

Anslag beviljat: 2021-2022

Mohamed Altai, FBKS-2021-29

Enhancing the antitumor activity of mAbs targeting the pan-cancer antigen Leucine-rich repeat-containing protein 15 (LRRC15)

Anslag beviljat: 2021-2022

Bodil Andersson, FBKS-2021-38

Serum protein biomarkers in bile duct cancer and pancreatic cancer

Anslag beviljat: 2021-2022

Mattias Belting, FBKS-2021-34

New strategies for the diagnosis and treatment of malignant brain tumors

Anslag beviljat: 2021-2022

Tommaso De Marchi, FBKS-2021-3

Neo-antigen identification for improved immunotherapy in locally recurring breast cancer

Anslag beviljat: 2021-2022

Sara Ek, FBKS-2021-6

Improved targeted therapeutic strategies for B cell lymphoma patients

Anslag beviljat 2021-2024

Pontus Eriksson, FBKS-2021-22

Differentiering och malign transformation av uro-epiteliala celler

Anslag beviljat: 2021-2022

Lennart Greiff, FBKS-2021-39

Cell-specific and spatially resolved features and functions of the myeloid compartment in virus-induced head and neck cancer

Anslag beviljat: 2021-2022

Ingrid Hedenfalk, FBKS-2021-16

Single Cell Resolution of the High-Grade Serous Ovarian Cancer Ecosystem Spatiotemporal Transcriptional Profiling to Address Disease Heterogeneity and Treatment Resistance

Anslag beviljat: 2021

Magnus Jakobsson, FBKS-2021-31

Personalized ovarian cancer therapy through multi-layered proteomics

Anslag beviljat: 2021-2022

Mats Jerkeman, FBKS-2021-2

Biobanking at the Department of Oncology - Securing an Infrastructure for the Decades to Come

Anslag beviljat: 2021-2024

Sylvia Jochems, FBKS-2021-20

Socioeconomic disparity in prostate cancer survival: is poor health the mediator?

Anslag beviljat: 2021

Göran Jönsson, FBKS-2021-35

The role of tertiary lymphoid structures shaping the anti-tumor immune response in cancer

Anslag beviljat: 2021

Balázs Kapás, FBKS-2021-41

National Population-based Retrospective Study on the Effect of Allogeneic Stem Cell Transplantation on Outcome in the Treatment of Lymphoma

Anslag beviljat: 2021-2022

Anna-Maria Larsson, FBKS-2021-25

Circulating biomarkers to improve prognostication and monitoring in metastatic breast cancer - with a translational focus on immune response

Anslag beviljat: 2021-2022

Johan Malm, FBKS-2021-7

The impact of malignant melanoma tumor heterogeneity on drug treatment effects at single-cell level – A prospective proteogenomic & digital pathology study

Anslag beviljat: 2021-2022

Per Munck af Rosenschöld, FBKS-2021-40

Self-learning Radiotherapy Clinic

Anslag beviljat: 2021-2022

Henrietta Nittby Redebrandt, FBKS-2021-32

Exploring the mechanism behind syngeneic effects of immune therapy and single- or double fractionated radiotherapy in glioblastoma

Anslag beviljat: 2021-2022

Lars E. Olsson, FBKS-2021-9

Predicting outcome after radiotherapy: A new approach

Anslag beviljat: 2021-2022

Håkan Olsson, FBKS-2021-19

Does a very high dose desloratadine improve anti tumour effects in combination with immune check point therapy

Anslag beviljat: 2021-2022

Lisa Rydén, FBKS-2021-11

Tamoxifen response in premenopausal patients by comprehensive genomic profiling in a randomized trial with long-term follow-up

Anslag beviljat: 2021-2022

Gottfrid Sjäodahl, FBKS-2021-36

Spatial transcriptomics and in situ resolution of heterogeneity in locally advanced and metastatic urothelial cancer

Anslag beviljat: 2021-2022

Johan Staaf, FBKS-2021-13

Integrativa genomiska studier av lungcancer

Anslag beviljat: 2021-2023

Johan Staaf, FBKS-2021-23

A research infrastructure for spatial and single cell analysis of tumors at Division of Oncology, Medicon Village, Lund University Cancer Center

Anslag beviljat: 2021-2024

Tanja Stocks Charles, FBKS-2021-12

Obesity, weight changes, and cancer risk in the Obesity and Disease Development Sweden (ODDS) study

Anslag beviljat: 2021-2023

Joanna Strand, FBKS-2021-24

Optimizing theranostics of prostate cancer with radionuclide therapy targeting PSA (KLK3)

Anslag beviljat: 2021-2022

David Ulmert, FBKS-2021-17

Development of a Novel Immuno-Theranostic Modality Targeting a TGF-Beta-driven Biomarker in Osteo- and Chondrosarcoma

Anslag beviljat: 2021-2022

Bo Åkerström, FBKS-2021-33

Protection of healthy tissue with the human radical scavenger A1M in cancer radiotherapy

Anslag beviljat: 2021-2022

Anders Örbom, FBKS-2021-10

Preclinical evaluation of co-treatment with Trastuzumab anti-HER2 antibody to improve efficacy of ¹⁷⁷Lu-PSMA-617 radionuclide therapy against metastatic castration-resistant prostate cancer

Anslag beviljat: 2021-2022